Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...

Discover how lifestyle risks are impacting cancer cases in Singapore and the multi-faceted approach needed for effective ...

Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in ...

Higher drug exposure in women due to lower renal and hepatic clearance and body composition can increase efficacy but also toxicity, highlighting the need to reassess dosing.

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, ...

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

Morgan Stanley Technology, Media & Telecom Conference 2026 March 3, 2026 12:15 PM ESTCompany ParticipantsEric Lefkofsky ...

Solid tumors, prevalent across various systems such as the respiratory, digestive, urinary, and gynecologic systems, constitute a significant challenge in adult oncology. These tumors are ...